Back to search
FDAFDA · Food and drugs·Recall number D-0866-2026

Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00.

Published September 23, 2026 · Recall initiated: August 21, 2026

Summary

FDA records drug Class I recall D-0866-2026, published September 23, 2026 and initiated August 21, 2026. Recalling firm: VITRUVIAS THERAPEUTICS INC; Status: Ongoing; Reported quantity: 1955 bottles; Lot: Lot # 504950, Exp Date: 09/30/2026. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent Drug

What to do

Voluntary: Firm initiated · Letter

Get an email if THYROID has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
THYROID
Manufacturer
VITRUVIAS THERAPEUTICS INC
Distributor
US Nationwide.
Lot
Lot # 504950, Exp Date: 09/30/2026.
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00. recalled?

Yes. FDA published recall D-0866-2026 on September 23, 2026. Reported hazard: Superpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: THYROID.